Acumen research and consulting estimates that the global human microbiome market is anticipated to reach market size of around US$ 1,700 Mn by 2027 and is anticipated to grow at a CAGR of around 22% in terms of revenue during the forecast period 2020 - 2027.
One of the key factors of the global human microbiome market is growing incidence of chronic diseases including diabetes, cancer, and obesity, as well as growing geriatric populations. For instance, in 2010, 285 million people worldwide had diabetes and it is estimated to hit $439 million by 2030, according to a report published by the National Biotechnology Information Centre (NCBI). With the rising incidence of diabetes, demand for human microbiome therapies for the treatment of the condition has risen dramatically. Furthermore, growing awareness of the benefits of microbiome products among people also leads to the global growth of the human microbiome industry. Stringent regulatory controls, however, prohibit the global microbiome market from increasing. Progress in biomedical research provides the worldwide microbiome market with resources. The global human microbiome market has been defined by growing mergers and acquisitions between key actors and government partnerships.
Rising Incidence of Metabolic Disorders to Propel Demand
The increased prevalence of cancer, Crohn's disease, and bowel syndrome have encouraged the development of the global human microbiome sector. In addition, the existence of many research centres, which specialise on human microbiomes, has also continued to expand the sector. The latest development of the health sector has been celebrated as the catalyst for expansion in the global market for human microbiomes. The research of human microbiome also includes treating metabolic conditions and diseases. This is another significant factor which has enriched human microbiome globally.
Growing Technological Advancements in Metagenomics and Next-generation Sequencing
Microbiome-based research was rendered simpler and cheaper by scientific developments in metagenomics and next-generation sequence, so the genomic level of microorganisms from human sample was rapidly evaluated. This has improved the microbiome-based diagnostic development process. Gastrointestinal and metabolic disorders are expected to gain leading share in 2019, as businesses are growing their interest in creating a simple therapeutic method for bowel syndrome and Crohn's disease for intestinal health disorders. While cancer is expected to gain a modest market share in 2019, which is considerably smaller than gut health and metabolic disorders, it is a business opportunity in the production of a diagnostic test to identify cancer. For example the diagnosis of colorectal cancer markers is established by Metabiomics. Colorectal cancer tests are focused on intrusive colonoscopy and, therefore, a rare opportunity for the organization to stand out in a market with enormous unfulfilled needs is a non-invasive procedure produced by Metabiomics (which uses a stool sample to determine the patient's microbiome of the gut).
Therapeutic Applications is Expected to hold the Highest Market Share
There are a number of organizations in the human microbiome space that develop products in different disease areas. Companies have developed their own proprietary systems for microbiome-based diagnosis and creative methods. A typical technique is to use real, live bacteria in a range of products, either as a single agent or as a combination. Any firms are developing and designing bacteria to take over other biochemical roles in order to combat unusual conditions.
In North America and Europe, the enhanced biotechnological and microbiological research facilities have dominated the global human microbiome market. In these countries, the rise in the incidences of life-style complications and autoimmune diseases has promoted the growth of the market for human microbiomes. The United States is the main human microbiome market in North America, followed by Canada. Germany, France, Spain and the United Kingdom are major markets in Europe. However, the global human microbiome market is projected to see strong growth in Asia Pacific in the next 5 years. This is because of the development of research infrastructure by several government agencies, by funding and supporting for work on life sciences, are promoting the advancement of the human microbiome industry in the region. The fastest rising human microbiome markets in Asia Pacific are projected to be China and India.
The global human microbiome market includes prominent players such as Merck, Yakult, DuPont, Enterome Bioscience, ViThera Pharmaceuticals, Second Genome Inc., Vedanta BioSciences, Microbiome Therapeutics LLC, Osel, Metabiomics Corporation, and others. The most adopted approach in the global human microbiome market has been patent and licence approvals.
The global human microbiome market is segmented as below:
Human Microbiome Market By Product
Human Microbiome Market By Disease
Human Microbiome Market By Application
Human Microbiome Market By Geography
Middle East & Africa
The market for human microbiome is expected to reach a market value of around US$ 1,700 Mn by 2027.
The human microbiome market is expected to grow at a CAGR of around 22% from 2020 to 2027.
The therapeutic is the leading segment by application in the human microbiome market.
Regulations by governmental bodies on probiotics and prebiotics would boost the market.
Merck, Yakult, DuPont, Enterome Bioscience, ViThera Pharmaceuticals, Second Genome Inc., Vedanta BioSciences, MicroBiome Therapeutics LLC, Osel, Metabiomics Corporation, and other are the prominent players in the market.
North America held the highest market share in the human microbiome market.
Asia Pacific is expected to be the fastest growing market over the forecast period.